Biotechnology

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

Aurinia Pharmaceuticals' deal for Kezar Life Sciences hinges on zetomipzomib, a promising but risky drug poised to tackle a rare autoimmune liver disease.

Japanese pharma giant Meiji Seika Pharma backs Centivax's quest for a universal flu vaccine, a move that could revolutionize global pandemic preparedness.

A Georgia firm's painless patch technology earns top honors, promising to revolutionize medicine delivery and solve critical global health challenges.

A $15M grant fuels a revolutionary therapy for a fatal childhood disease, turning patients' own cells into 'living biofactories' to fight MPS I.

After promising results in a key patient subgroup, the PREVAiLS study will test if pridopidine can slow the relentless progression of ALS.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.

PMGC Holdings touts major acquisitions and a promising biotech pipeline, but a look at its financials reveals a high-stakes bet on future growth.

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.

Global CRO ChemPartner launches a new research site in Kent's Discovery Park, a major strategic push to accelerate drug development for European clients.

A new national scholarship from longevity expert Dr. Sajad Zalzala aims to empower future healthcare professionals to tackle the root causes of disease.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

The Norwegian innovator reports strong operational progress but faces uncertainty as a crucial NOK 158 million share placement is delayed until Q2 2026.

After its pivotal trial for ersodetug missed its primary endpoint, Rezolute gets a rare nod from the FDA to submit full data, igniting new hope.

Dr. Lisa G. Roth, a top oncologist and survivor, takes the helm at Hassenfeld, promising a new era of 'whole person' care for young cancer patients.

A landmark partnership is scaling a 'one-drug, many-diseases' therapy, revealing how logistics, not just labs, are key to the future of medicine.

Navigator Medicines pushes two novel bispecific antibodies for Hidradenitis Suppurativa, promising better efficacy and patient-friendly dosing.

A $520K state grant will provide firefighters with a new AI-powered blood test, highlighting a major push to protect high-risk first responders.